One of the biggest challenges in cancer therapy has always been precision. Antibody-drug conjugates (ADCs) offer a sophisticated solution that delivers highly potent cytotoxic agents directly to ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to ...

Antibody–drug conjugates (ADCs) represent a breakthrough in cancer therapy, combining the precision of monoclonal antibodies with powerful chemotherapeutic drugs. While ADC development is accelerating ...

While they have been around for some years, ADCs – which pair antibodies with a drug payload designed to boost their efficacy – are gathering momentum in biopharma drug development as early ...

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to $1.14bn, representing another big-dollar deal for the promising cancer ...

Taiho Pharmaceutical Co., Ltd., an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases, and Araris Biotech AG, a Swiss biotechnology company developing ...

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload ...

The Japanese pharmaceutical company Taiho Pharmaceutical is set to acquire the Swiss antibody-drug conjugate (ADC) company Araris Biotech for $400 million. Taiho and Araris have been collaborating ...

ADCs are designed to selectively deliver cytotoxic drugs (payloads) to cancer cells by attaching them to antibodies that bind specifically to cancer cells through linkers. Foundational to its ...

Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho Pharmaceutical") and Araris Biotech AG (hereinafter "Araris"), a Swiss biotechnology company developing next-generation antibody drug conjugates ...